Botulinum toxin type A injections for the management of flexion contractures following total knee arthroplasty.

Thorsten M. Seyler, Riyaz H. Jinnah, L. Andrew Koman, David R. Marker, Michael A. Mont, Slif D. Ulrich, Anil Bhave

Research output: Contribution to journalArticlepeer-review

Abstract

The development of knee flexion contractures following total knee arthroplasty is detrimental to a patient's functional capabilities. Despite using aggressive rehabilitative modalities postoperatively, some knee arthroplasty patients do not respond and continue to experience muscle spasms. Botulinum toxin type A has been used as a temporary neuromuscular transmitter blocker to treat muscle spasms in patients with neurological disorders, and it has been utilized as a treatment method for clubfoot. The purpose of this study was to evaluate botulinum toxin type A as a new treatment modality for patients with flexion contractures following total knee arthroplasty that were recalcitrant to standard treatment methods. By 2 years following injections, 9 out of 11 knees achieved extension within 10; of neutral position, and 8 of the 11 maintained this improved range of motion by a mean follow-up of 36 months. There were two failures in patients who had a revision knee arthroplasty, suggesting that this treatment is more effective in patients following primary cases. Based on these results, botulinum toxin type A should be considered as a potential treatment modality, especially in difficult-to-treat cases of knee flexion contracture that are recalcitrant to standard therapy.

Original languageEnglish (US)
Pages (from-to)231-238
Number of pages8
JournalJournal of surgical orthopaedic advances
Volume17
Issue number4
StatePublished - Jan 1 2008

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Botulinum toxin type A injections for the management of flexion contractures following total knee arthroplasty.'. Together they form a unique fingerprint.

Cite this